Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$0.75 USD
-0.01 (-1.57%)
Updated May 8, 2024 03:59 PM ET
After-Market: $0.75 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNPR 0.75 -0.01(-1.57%)
Will MNPR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Other News for MNPR
12 Health Care Stocks Moving In Friday's After-Market Session
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Monopar files patent protecting its MNPR-101 radiopharma optimization findings
Monopar Therapeutics Advances Radiopharmaceuticals with New Patent